z-logo
open-access-imgOpen Access
Protein transduction by pseudotyped lentivirus-like nanoparticles
Author(s) -
Takuya Aoki,
Katsumi Miyauchi,
Emiko Urano,
Reiko Ichikawa,
Jun Komano
Publication year - 2011
Publication title -
gene therapy
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 1.332
H-Index - 159
eISSN - 1476-5462
pISSN - 0969-7128
DOI - 10.1038/gt.2011.38
Subject(s) - transduction (biophysics) , biology , hek 293 cells , transfection , myristoylation , microbiology and biotechnology , signal transduction , capsid , vesicular stomatitis virus , cell culture , virology , biochemistry , phosphorylation , virus , genetics
A simple, efficient and reproducible method to transduce proteins into mammalian cells has not been established. Here we describe a novel protein transduction method based on a lentiviral vector. We have developed a method to package several thousand foreign protein molecules into a lentivirus-like nanoparticle (LENA) and deliver them into mammalian cells. In this proof-of-concept study, we used β-lactamase (BlaM) as a reporter molecule. The amino-terminus of BlaM was fused to the myristoylation signal of lyn, which was placed upstream of the amino-terminus of Gag (BlaM-gag-pol). By co-transfection of plasmids encoding BlaM-gag-pol and vesicular stomatitis virus-G (VSV-G) into 293T cells, LENA were produced containing BlaM enzyme molecules as many as Gag per capsid, which has been reported to be ∼5000 molecules, but lacking the viral genome. Infection of 293T and MT-4 cells by VSV-G-pseudotyped BlaM-containing LENA led to successful transduction of BlaM molecules into the cell cytoplasm, as detected by cleavage of the fluorescent BlaM substrate CCF2-AM. LENA-mediated transient protein transduction does not damage cellular DNA, and the preparation of highly purified protein is not necessary. This technology is potentially useful in various basic and clinical applications.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here